Home
PFS & Injectable Drug Devices West Coast
June 8 - June 10, 2026
PFS & Injectable Drug Devices West Coast

FREE TO ATTEND FOR PHARMA AND BIOTECH

REGISTER HERE!

Foster Innovation and Collaboration at the 10th Annual Pre-Filled Syringes and Injectable Drug Devices West Coast Conference!

Join us in June 2026 as SAE Media Group’s renowned West Coast event returns, bringing together biotech pioneers, pharma leaders, and device innovators to shape the future of injectable drug delivery.

This year’s conference will bring a brand NEW focus day followed by the two-day main conference offering an unparalleled platform to explore cutting-edge advances in combination product technology while fostering collaboration between pharma, device developers, and regulators.

What You’ll Gain:

  • Actionable insights to strengthen your drug-device portfolio.
  • Opportunities to network with key players shaping the injectable drug delivery landscape.
  • A future-focused perspective on innovation, regulation, and patient-centric care.

This must-attend event is your chance to stay ahead in the rapidly evolving injectable drug delivery space. We look forward to welcoming you to the West Coast in June 2026!
 

FEATURED SPEAKERS

Andrew Kraszewski

Andrew Kraszewski

Product Development Research Engineer, Bristol Myers Squibb
Aniket Badkar

Aniket Badkar

Sr. Director and Head of Drug Product and Device Development, Vir Biotechnology
Aniket Badkar

Aniket Badkar

Sr. Director and Head of Drug Product and Device Development, Vir Biotechnology
Brendan Cummings

Brendan Cummings

Assistant Director, Drug Delivery Device Development, Ionis Pharmaceuticals, Inc
Chuck Ventura

Chuck Ventura

Chief Executive Officer, Ventura Solutions
Daphne King

Daphne King

Associate Director, Acadia Pharmaceuticals
Gurmeet Singh

Gurmeet Singh

Senior Director, Business Development, West Pharmaceutical Service
James Wabby

James Wabby

Head, Global Regulatory Affairs (CoE) - Emerging Technologies, Combination Products, and Devices, AbbVie
James Wabby

James Wabby

Head, Global Regulatory Affairs - (CoE): Emerging Technologies, Combination Products, and Devices, AbbVie
John Merhige

John Merhige

Co-CEO, Credence MedSystems, Inc.
Khaudeja Bano

Khaudeja Bano

Vice President - Global Head of Device Quality, Genentech
Khaudeja Bano

Khaudeja Bano

Vice President - Global Head of Device Quality, Genentech
Kinsuk Shah

Kinsuk Shah

Sr. AD Combination Product Steward, Boehringer Ingelheim
Mahendran Ravichandran (SUBJECT TO FINAL CONFIRMATION)

Mahendran Ravichandran (SUBJECT TO FINAL CONFIRMATION)

Director, R&D Combination Product Development, AbbVie
Mayumi Bowen

Mayumi Bowen

Senior Principal Engineer, Genentech
Mitch  Zhao

Mitch Zhao

Distinguished Engineer, JnJ Innovative Medicine
Natalie Abts

Natalie Abts

Director, Head of Human Factors Engineering, Genentech
Phil Estepa

Phil Estepa

Executive Director, Pharmaceutical Development, Ionis Pharmaceuticals
Protagonist Therapeutics - Representative

Protagonist Therapeutics - Representative

, Protagonist Therapeutics
Ronald Forster

Ronald Forster

Head of Combination Products Operations, Amgen
Sujit Basu

Sujit Basu

Vice President & Head, Pharmaceutical Development, Ionis Pharmaceuticals
Tycho Speaker

Tycho Speaker

Senior Principal Research Scientist, AbbVie

Andrew Kraszewski

Product Development Research Engineer, Bristol Myers Squibb
Andrew Kraszewski

Andrew Kraszewski has been a Product Development Research Engineer in Human Factors Engineering at Bristol Myers Squibb since 2024. He supports early-stage drug–device combination product development, translating patient and HCP insights into product requirements and partnering with device teams to benchmark platforms and define key attributes. At BMS, he has led usability research on caregiver interaction with injectable devices in simulated at-home settings, informing patient centric design for parenteral delivery systems. He previously worked in biomechanics research and has led and supported many clinically-oriented studies and publications. Andrew lives in NYC and enjoys the outdoors.

Aniket Badkar

Sr. Director and Head of Drug Product and Device Development, Vir Biotechnology
Aniket Badkar

Dr. Aniket Badkar is Director, Pharmaceutical Product Development at Vir Biotechnology where he leads biologics and combination product development of Vir’s pipeline. Prior to joining Vir Biotechnology, Dr. Badkar served multiple positions of increasing responsibilities at Abbvie Inc., Zoetis, Inc. and Merck, Inc. developing biologic products for parenteral, ocular and topical delivery. He has led the technical development and / or life cycle innovation of several biologic products such as Cytopoint™, Tildrakizumab, Brazikumab and Botox®. Dr. Badkar has a Ph.D. in Pharmaceutical Sciences from Mercer University and a BS in Pharmacy from University of Mumbai, India.

BD - Senior Representative

, BD
BD - Senior Representative

Brendan Cummings

Assistant Director, Drug Delivery Device Development, Ionis Pharmaceuticals, Inc
Brendan Cummings

Brendan Cummings is a medical device professional with 13 years of industry experience. He has successfully commercialized products across 5 different product families spanning cardiac catheters, stents, heart valves, and drug delivery devices. He has an undergraduate and masters degree in biomedical engineering with a focus on mechanical design and product development.

Chuck Ventura

Chief Executive Officer, Ventura Solutions
Chuck Ventura

Chuck Ventura is the CEO and Founder of Ventura Solutions, a leading consulting, engineering, staffing, and training firm specializing in combination products. For nearly a decade, Ventura Solutions has served as a trusted partner to medical device, pharmaceutical and biotech companies, providing deep expertise in regulatory strategy, quality systems, design control, risk management, human factors, and more.


With close to 20 years of experience, Chuck has dedicated his career to advancing the development of combination products and medical devices. Prior to founding Ventura Solutions, he co-founded Hemotek Medical, where he served as CEO and led the development of a novel, life-saving needle for hemodialysis. Under his leadership, the product earned FDA Breakthrough Device Designation, IDE approval, global patents, and progressed through clinical trials to a successful commercial exit.


Earlier in his career, Chuck held leadership roles at Baxter, Hospira, and Pfizer, where he served as R&D Engineering Manager for Combination Products. He played a pivotal role in implementing the FDA’s 21 CFR Part 4 regulation, developing and executing some of the first combination product Design History Files (DHFs) and risk management files, which passed FDA audits with zero observations.


Chuck holds a BS in Biomedical and Electrical Engineering from the University of Illinois at Chicago and an MS in Mechanical and Aerospace Engineering from the Illinois Institute of Technology. His entrepreneurial vision and practical expertise make him a trusted leader in bringing combination products from concept to commercialization.

Daphne King

Associate Director, Acadia Pharmaceuticals
Daphne King

Datwyler - Senior Representative

, Datwyler
Datwyler - Senior Representative

EdgeOne Medical - Senior Representative

, EdgeOne Medical
EdgeOne Medical - Senior Representative

FDA - Representative to be confirmed

, FDA
FDA - Representative to be confirmed

Gurmeet Singh

Senior Director, Business Development, West Pharmaceutical Service
Gurmeet Singh

Gurmeet Singh is a senior director, Business Development at West Pharmaceuticals. Gurmeet has been with West for 10 years. In this role, she manages a global team that collaborate with strategic large and mid cap pharmaceutical co’s, to sell services and solutions to support the development of Combination products to bring optimal drug delivery options for patients, caregivers and providers. These CP’s may include West Proprietary product platforms and services include taking it all the way from design, development through clinical readiness and finally scale up and manufacturing.

Experienced Business leader in the pharmaceutical packaging including drug delivery devices for injectable drugs. Strong focus in Combination product development and commercialization projects working with multiple global Pharmaceutical partners. Passionate about bringing to our customers innovative solutions that are designed with the patient in mind, with the intent to improve their lives. Knowledgeable and experienced professional supporting all aspects of device development, cGMP manufacturing as well as global regulatory compliance.
 

Haselmeier - Senior Representative

, Haselmeier
Haselmeier - Senior Representative

James Wabby

Head, Global Regulatory Affairs - (CoE): Emerging Technologies, Combination Products, and Devices, AbbVie
James Wabby

John Merhige

Co-CEO, Credence MedSystems, Inc.
John Merhige

John A. Merhige is Chief Commercial Officer at Credence MedSystems, leading the Company's commercial activities and external collaborations. Previously, John was Vice President, Market Development at Sanofi BioSurgery. He came to Sanofi upon its acquisition of Pluromed in 2012, which John joined in its early stages and where he was a member of the executive management team. He led the commercial activities at Pluromed, which developed and commercialized highly innovative rapid transition polymers for use in cardiovascular and other surgical procedures.

Prior to Pluromed, John founded Prelude Devices to target early stage medical device technologies for development and commercialization, and previously he gained general management and leadership experience at Ford Motor Company and Avery Dennison.

John graduated from Dartmouth College earning a BA, a BE in mechanical engineering, and a Masters in Engineering Management from Dartmouth’s Thayer School of Engineering and Tuck School of Business. John is married with three children.

Kailera Therapeutics - Senior Representative

, Kailera Therapeutics
Kailera Therapeutics - Senior Representative

Khaudeja Bano

Vice President - Global Head of Device Quality, Genentech
Khaudeja Bano

Khaudeja is a Physician with a Masters in Clinical Research, Pharmaceutical engineering Certification, a Database Administrator and a certified Project Management Professional.

Khaudeja has more than 25 years’ professional experience, including clinical practice. She has held several global medical positions at Guidant, Abbott, AbbVie Inc and Amgen. Her career includes global medical / clinical
and safety leadership roles in devices, diagnostics, pharmaceuticals and combination products.

She currently serves as the chair for the Post Marketing Safety working group for the Combination Product Coalition (CPC).
 

Kindeva - Senior Representative

, Kindeva
Kindeva - Senior Representative

Kinsuk Shah

Sr. AD Combination Product Steward, Boehringer Ingelheim
Kinsuk Shah

Kinsuk Shah is currently Sr. AD, Combination Product Steward at Boehringer Ingelheim, responsible for device lifecycle management and strategy for Cyltezo. Mr. Shah is accountable for continuing development and oversight of CP manufacturing + supply, leading an interdisciplinary team of internal SMEs (e.g., drug product, packaging, final assembly, device, quality). Prior to joining BI, Mr. Shah was Director of Device Development at Viridian Therapeutics, responsible for device strategy and development, including establishing internal and external capabilities within the device space, evaluation and selection of wearable and auto-injector devices. Mr. Shah has over 10 years of drug-device combination product experience from Janssen, West and Alexion. Prior to Viridian, Mr Shah was at Alexion, where he was responsible for Strategy and Program Management for ongoing device dependent programs. At West Mr Shah was the Business Development lead for the SmartDose and SelfDose platforms, successfully partnering with multiple pharmaceutical companies in establishing joint combination product programs for each product.

Mahendran Ravichandran (SUBJECT TO FINAL CONFIRMATION)

Director, R&D Combination Product Development, AbbVie
Mahendran Ravichandran (SUBJECT TO FINAL CONFIRMATION)

Mayumi Bowen

Senior Principal Engineer, Genentech
Mayumi Bowen

Mitch Zhao

Distinguished Engineer, JnJ Innovative Medicine
Mitch  Zhao

• 20+ years at JNJ
o 16+ years at JNJ Innovative Medicine as a multi-discipline drug/device combination product development team leader responsible for developing primary containers and drug delivery devices for various programs including guselkumab (Tremfya) and ustekinumab (Stelara)
o 4 years at JNJ MedTech as technical leader on insulin pump and infusion set development
• 6 years at two biotech companies in the bay area as team leader on developing microfluidic chips for bioanalytical applications
• 10 issued patents and ~ 10 pending patents on drug delivery devices and microfluidics;
• Over 20 peer-reviewed papers with total citations of > 8000
• Ph.D in Chemistry; B.En and M. En in App. Chem.

 

Mitsubishi Gas Chemical - Senior Representative

, Mitsubishi Gas Chemical
Mitsubishi Gas Chemical - Senior Representative

Natalie Abts

Director, Head of Human Factors Engineering, Genentech
Natalie Abts

Phil Estepa

Executive Director, Pharmaceutical Development, Ionis Pharmaceuticals
Phil Estepa

Phil is the Executive Director Pharmaceutical Development & Head of Devices at Ionis Pharmaceuticals. Phil has 20 years of experience in combination product R&D, Development and Manufacturing. He has been instrumentally involved in device strategy, delivery innovation, tech transfer-scale up and setting up manufacturing sites domestically and globally.
Prior to Ionis Pharmaceuticals, Phil has worked for Xeris Pharmaceuticals, Kaleo Pharma, Apricus Biosciences, Amylin-Bristol Myers Squib-AstraZeneca Alliance and Medtronic in various roles from Principal Engineer to Executive Leadership in the successful development and commercialization of 11 Combination Products.
Phil holds two issued patents in medical and drug delivery devices and has multiple patent applications. His education includes undergraduate studies Industrial Engineering Technology locally from San Diego State University, with an emphasis in plastics/polymer science. Prior to his life science career, Phil was involved in aerospace engineering in the development of the Apache Helicopter, F-18 Super Hornet, A-12 Avenger, and multiple UAV aircraft used in today’s defense strategy.

Protagonist Therapeutics - Representative

, Protagonist Therapeutics
Protagonist Therapeutics - Representative

Representative to be confirmed

, Protagonist Therapeutics
Representative to be confirmed

Representatives to be confirmed

, BioPhorum
Representatives to be confirmed

Ron Forster

Head of Combination Products Operations , Amgen
Ron Forster

Ronald Forster

Head of Combination Products Operations, Amgen
Ronald Forster

SHL Medical - Senior Representative

, SHL Medical
SHL Medical - Senior Representative

SteriTek - Senior Representative

, SteriTek
SteriTek - Senior Representative

Sujit Basu

Vice President & Head, Pharmaceutical Development, Ionis Pharmaceuticals
Sujit Basu

Dr. Basu is currently the Head of Pharmaceutical Development at Ionis. Dr. Basu’s prior experiences include serving as Vice President, Pharmaceutical Sciences, and Pharmaceutical Development at Takeda/Shire where he led the Device and Combination Products Center of Excellence that was responsible for development and commercialization of delivery devices and combination products, digital health, and diagnostic solutions, as well as Vice President at Dicerna Pharmaceuticals (now part of Novo Nordisk). Dr. Basu studied Pharmaceutical Technology and Engineering (BS & MS) in Kolkata, India (Jadavpur University), Pharmaceutical Sciences (PhD) in Los Angeles (USC) and Certificate in Management in Cambridge, MA (Harvard).

Suttons Creek - Senior Representative

, Suttons Creek
Suttons Creek - Senior Representative

Tycho Speaker

Senior Principal Research Scientist, AbbVie
Tycho Speaker

Tycho Speaker, PhD, is a senior principal research scientist in AbbVie’s Combination Product Development and Drug Delivery organization, focused on injectable and skin interfacing delivery systems. He is also founder and CEO of Capsulent, a specialty materials company built on micro- encapsulation and charged polymer complex platform technologies, and he advises multiple early stage biotech and materials startups. Tycho serves on the PATH microneedle array patch regulatory working group and contributes to global health vaccine delivery efforts. He is an inventor on numerous patents and publications, and holds a PhD in physical chemistry from UC Santa Cruz.

sponsors

Conference agenda

clock

8:00

Registration & Coffee

clock

8:50

Chair's Opening Remarks

Sujit Basu, Vice President & Head, Pharmaceutical Development, Ionis Pharmaceuticals

clock

9:00

Strategic Clinical Pathways for Developing Combination Products with Emerging Technologies

James Wabby

James Wabby, Head, Global Regulatory Affairs - (CoE): Emerging Technologies, Combination Products, and Devices, AbbVie

  • Aligning clinical plans early to ensure drug–device integration supports safety, performance and regulatory expectations
  • Using phase-appropriate investigational device approaches to balance development flexibility with clinical and regulatory compliance
  • Incorporating human factors, usability data and risk management to validate safe and effective real-world use
  • Building bridging strategies that support transition from investigational to commercial devices without disrupting timelines or evidence generation
  • clock

    9:30

    Session Reserved for Sponsor

    clock

    10:00

    QMSR Readiness and Quality System Alignment for Combination Products

    Khaudeja Bano, Vice President - Global Head of Device Quality, Genentech

  • Interpreting FDA QMSR expectations and their impact on combination-product development and lifecycle management
  • Aligning pharmaceutical and medical device quality systems to enable compliant design, development and manufacturing pathways
  • Embedding risk management, design controls and documentation practices that support both drug and device regulatory frameworks
  • Preparing organizations for inspection readiness by strengthening data integrity, traceability and cross-functional quality governance
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Early Stage Strategies to Align Clinical Agility with CMC for PFS and Injectable Programs

    Representative to be confirmed

    Representative to be confirmed, , Protagonist Therapeutics

  • Why clinical teams pivot quickly while CMC and device development paths cannot shift as fast
  • Approaches to maintaining flexibility to accommodate evolving clinical needs
  • How to set early assumptions and scenarios to manage extractables and leachables, container closure integrity, viscosity and dose volume, and human factors timing
  • Practical lessons from real early-stage pivots and how to keep both teams aligned
  • clock

    11:30

    Session Reserved for Sponsor

    clock

    12:00

    Session Reserved for Regeneron

    Representative to be confirmed

    Representative to be confirmed, , Regeneron

    clock

    12:30

    Networking Lunch

    clock

    13:30

    Human Factors as a Strategic Lever: Integrating User Insight Across the Combination Product Lifecycle

    Natalie Abts

    Natalie Abts, Director, Head of Human Factors Engineering, Genentech

  • Embedding human factors early and often so cross-functional teams from early research through commercial labelling can use user insights to shape device strategy, reduce downstream risk and accelerate regulatory alignment
  • Addressing evolving complexity in combination products, including new modalities, emergency-use injectables, wearables and large-volume delivery systems
  • Examining which human factors frameworks best address novel risks while maintaining patient centricity and market differentiation
  • clock

    13:30

    Ensuring Market Success: Usability and Performance of Autoinjectors

    Mitch Zhao, Distinguished Engineer, JnJ Innovative Medicine

  • Anticipating and mitigating usability issues that emerge post-launch despite successful design verification
  • Identifying common usability challenges associated with autoinjectors and how human factors analysis can help address them earlier
  • clock

    13:30

    QMSR Readiness in Practice for Combination Products

    Khaudeja Bano, Vice President - Global Head of Device Quality, Genentech

  • Practically adapting quality systems to meet QMSR expectations for combination products, including integration challenges between pharmaceutical and device frameworks
  • Exchanging lessons learned related to traceability, documentation hand-offs and cross-functional ownership in real working environments
  • clock

    13:30

    Partnership Models for Injectable Drug Delivery: From Alignment to Execution

    Kinsuk Shah, Sr. AD Combination Product Steward, Boehringer Ingelheim

  • Operationalizing collaboration so pharma companies, CDMOs/CMOs and device partners can streamline governance, technology transfer and decision-making
  • Accelerating development and scale-up through clearer ownership and alignment
  • Sustaining long-term value by harmonizing incentives, performance expectations and risk sharing across the product lifecycle
  • clock

    15:00

    Afternoon Networking Break

    clock

    15:30

    Sustainable Drug Delivery Devices: Advancing a Unified Industry Framework for Life Cycle Analysis and Material Decisions

    Representatives to be confirmed

    Representatives to be confirmed, , BioPhorum

  • Reflecting on how sustainability recommendations have been applied since 2025, highlighting areas of progress, divergence and key learnings across drug delivery devices
  • Shifting from guidance to execution with practical, comparable life cycle analysis approaches to better support industry decision making
  • Exploring pathways to more sustainable material choices, balancing environmental impact with patient safety, performance and regulatory expectations
  • Strengthening cross industry collaboration to embed sustainability into device design, supplier engagement and portfolio-level planning
  • clock

    16:00

    Session Reserved for Sponsor

    clock

    16:30

    Focus Day Closing Panel: Designing Combination Products for Robust, Scalable Manufacturing

  • Aligning primary container closure integrity with process monitoring and inline physical methods
  • Ensuring manufacturability during scale up and global tech transfers
  • Optimizing cold chain and secondary packaging to safeguard product quality
  • Building cross functional systems that reduce risk and accelerate reliable market supply
  • Ron Forster

    Ron Forster, Head of Combination Products Operations , Amgen

    Sujit Basu, Vice President & Head, Pharmaceutical Development, Ionis Pharmaceuticals

    Tycho Speaker, Senior Principal Research Scientist, AbbVie

    Aniket Badkar, Sr. Director and Head of Drug Product and Device Development, Vir Biotechnology

    clock

    17:00

    Chair’s Closing Remarks and End of Focus Day

    Sujit Basu, Vice President & Head, Pharmaceutical Development, Ionis Pharmaceuticals

    clock

    8:00

    Registration & Coffee

    clock

    8:50

    Chair's Opening Remarks

    Kinsuk Shah, Sr. AD Combination Product Steward, Boehringer Ingelheim

    clock

    9:00

    Current Landscape and Emerging Technologies for Injectable Drug Delivery

    Sujit Basu, Vice President & Head, Pharmaceutical Development, Ionis Pharmaceuticals

  • Examining the evolving landscape of emerging drug product modalities and the technologies shaping the future of injectable drug delivery
  • Identifying key industry challenges within the emerging-technology space and exploring practical strategies to overcome them, highlighting where innovation efforts should be focused to accelerate progress across development and delivery
  • clock

    9:30

    Session Reserved for Suttons Creek

    Suttons Creek - Senior Representative

    Suttons Creek - Senior Representative, , Suttons Creek

    clock

    10:00

    Tissue Target as a Component in Injection Devices

    Tycho Speaker, Senior Principal Research Scientist, AbbVie

  • Recognising tissue as part of the system model from the beginning, with skin and subcutis acting as rate-dependent and variable components that drive backpressure, displacement and user experience
  • Understanding delivery dynamics including depot and bleb formation, swelling and anisotropic spread that can create tipping points leading to leakback
  • Examining formulation and device coupling where considering tissue as part of the device mechanism can affect force and time requirements
  • Using design levers where fluid path geometry extends beyond the needle and where depth and event timing explicitly include tissue response
  • Applying practical verification methods including pressure and force signatures alongside benchtop and imaging approaches
  • Reviewing a mini case study on novel approaches to skin stabilisation during penetration in microneedle-mediated delivery
  • clock

    10:30

    Morning Networking Break

    clock

    11:00

    Session Reserved for SHL Medical

    SHL Medical - Senior Representative

    SHL Medical - Senior Representative, , SHL Medical

    clock

    11:30

    Panel Discussion Designing Predictable, Patient Centric Drug Device Platforms for Future Ready Drug Delivery

  • Preparing for a future where self management and self injection dominate, identifying priority use scenarios and device must haves
  • Anticipating major market shifts in injectable combination products and the operating model and early engineering choices that most determine long term success
  • Improving predictability in regulatory submissions and post approval change processes especially around evidence expectations while defining success in terms of speed, supply resilience and lifecycle agility
  • From submissions to the future: Aligning claims, requirements, and control strategies to enable scalable platforms and optional connectivity while identifying the single near term action that best positions teams for the next decade
  • Phil Estepa, Executive Director, Pharmaceutical Development, Ionis Pharmaceuticals

    Chuck Ventura, Chief Executive Officer, Ventura Solutions

    Daphne King

    Daphne King, Associate Director, Acadia Pharmaceuticals

    Natalie Abts

    Natalie Abts, Director, Head of Human Factors Engineering, Genentech

    clock

    12:00

    Simplifying the journey from vial to self-administration

    Gurmeet Singh, Senior Director, Business Development, West Pharmaceutical Service

  • A holistic approach to ensure smooth transition from vial-based containment to fully integrated drug delivery combination products accelerating time to market and ensuring reliability, patient safety and comfort
  • As pharmaceutical manufacturers look to enhance patient adherence, improve dosing accuracy, and enable self administration, many are transitioning from simple vial formats to integrated drug device combination products
  • This session will cover key considerations and demonstrate how leveraging a verified, device platform minimizes development risk and accelerates timelines across human factors, regulatory alignment, and manufacturing scale-up through commercialization
  • clock

    12:30

    Networking Lunch

    clock

    13:30

    FDA Perspectives and Updates in Injectable Drug Delivery Device Development

    FDA - Representative to be confirmed

    FDA - Representative to be confirmed, , FDA

  • A comprehensive review of recent and upcoming FDA guidance for combination products, including emerging expectations for EDDOs and evolving regulations impacting combination product development
  • Practical strategies for effective communication, regulatory compliance, and partnership between pharma, device manufacturers and FDA aimed at streamlining approval processes and improving market access
  • clock

    14:00

    An Innovation Platform Approach to Solving Challenges in Injectable Drug Delivery

    John Merhige, Co-CEO, Credence MedSystems, Inc.

  • Industry trends and the drug delivery challenges they are driving
  • Using innovation and a platform approach to address these challenges
  • Advantages of a delivery system platform approach
  • clock

    14:30

    Container Closure Integrity Testing Solutions for Complex Injectables Devices

    Brendan Cummings, Assistant Director, Drug Delivery Device Development, Ionis Pharmaceuticals, Inc

  • Limitations of current container closure integrity methods with autoinjectors and pen injectors
  • Overview and comparison of container closure integrity technologies
  • Description of laser headspace technology and method
  • Successful method validation results across multiple devices and container formats
  • clock

    15:00

    Afternoon Networking Break

    clock

    15:30

    Session Reserved for Haselmeier

    Haselmeier - Senior Representative

    Haselmeier - Senior Representative, , Haselmeier

    clock

    16:00

    Human Factors at the Frontiers of Combination Product Innovation

    Natalie Abts

    Natalie Abts, Director, Head of Human Factors Engineering, Genentech

  • Embedding human factors into the development of emerging delivery systems such as high-volume injectors and novel container closures where industry precedents are limited
  • Practical approaches to identify and mitigate integration risks driven by formulation properties, primary packaging and real-world use conditions
  • Reviewing decision pathways for evolving regulatory expectations and developing frameworks to plan human factors activities when global guidance is sparse, shifting or non-prescriptive while still supporting robust submissions
  • Lessons from cross functional alignment across quality, regulatory and clinical teams to demonstrate how strategic human factors input reduces late stage challenges and strengthens product differentiation
  • clock

    16:30

    Session Reserved for Mitsubishi Gas Chemical

    Mitsubishi Gas Chemical - Senior Representative

    Mitsubishi Gas Chemical - Senior Representative, , Mitsubishi Gas Chemical

    clock

    17:00

    Understanding Pediatric Caregiver Preference Safety Syringe vs Autoinjector

    Andrew Kraszewski, Product Development Research Engineer, Bristol Myers Squibb

  • Problem Statement and Objectives: Pediatric therapies shifting to home, challenges and potential unmet needs
  • Study Protocol & Methods: Simulation & Questionnaire At-home data collection
  • Results: Who we spoke with, Major IDI themes, Qualitative and quantitative readout
  • Conclusion & Takeaways: Study limitations, Preferred device and Recommendations
  • clock

    17:30

    Chair’s Closing Remarks and Close of Day One

    Kinsuk Shah, Sr. AD Combination Product Steward, Boehringer Ingelheim

    clock

    8:00

    Registration & Coffee

    clock

    8:50

    Chair's Opening Remarks

    Kinsuk Shah, Sr. AD Combination Product Steward, Boehringer Ingelheim

    clock

    9:00

    Optimizing Drug-Device Combination Product Development Timelines: Considerations and Streamlined Collaboration

    Mahendran Ravichandran (SUBJECT TO FINAL CONFIRMATION)

    Mahendran Ravichandran (SUBJECT TO FINAL CONFIRMATION), Director, R&D Combination Product Development, AbbVie

  • Evaluating tailored versus platform solutions by comparing the benefits of designing devices for specific drugs against leveraging adaptable platform devices for broader applications
  • Successfully transitioning from vial to subcutaneous administration by applying key strategies and considerations that ensure a smooth process
  • Fostering cross-functional collaboration between drug and device R&D teams to align objectives and streamline device development
  • clock

    9:30

    Session Reserved for BD

    BD - Senior Representative

    BD - Senior Representative, , BD

    clock

    10:00

    Aligning Manufacturing, Quality, and Regulatory Readiness Across Combination Product Lifecycle

    Kinsuk Shah, Sr. AD Combination Product Steward, Boehringer Ingelheim

  • Establishing end-to-end oversight for combination product manufacturing and supply to ensure seamless integration between drug, device, packaging and assembly functions
  • Building and coordinating a cross-functional network of subject matter experts to drive consistent quality, risk mitigation and compliance throughout development and commercialization
  • Strengthening regulatory preparedness by clearly articulating combination product interfaces during health authority inspections and addressing evolving expectations
  • Embedding combination product considerations into lifecycle management to support sustained product performance, post-market vigilance and continuous improvement
  • clock

    10:30

    Morning Networking Break

    clock

    11:00

    Session Reserved for SteriTek

    SteriTek - Senior Representative

    SteriTek - Senior Representative, , SteriTek

    clock

    11:30

    Designing CNS Delivery Systems: From User Needs to Verification

    Mayumi Bowen

    Mayumi Bowen, Senior Principal Engineer, Genentech

  • Selecting optimal design requirements to reach specific target brain regions based on anatomy, dosing needs and route constraints
  • Identifying failure modes and potential human error to ensure patient safety and maintain critical quality attributes through effective risk management
  • Proving performance and usability through a phase-appropriate verification and validation evidence package
  • Solving drug-device fit challenges related to material compatibility, drug stability and manufacturing scale-up
  • Navigating regulatory pathways including 510(k) and PMA challenges when leveraging standalone or investigational devices
  • Collaborating strategically with device manufacturers to align drug-device decisions and streamline development
  • clock

    12:00

    Session Reserved for Datwyler

    clock

    12:30

    Networking Lunch

    clock

    13:30

    The evolving Regulatory Landscape for Drug-Device Combination Products: A CMC Perspective

    Daphne King

    Daphne King, Associate Director, Acadia Pharmaceuticals

  • Implementing MDR requirements with attention to timelines and new regulatory obligations
  • Managing the replacement of IVDD with IVDR and understanding implications for legacy devices
  • Transitioning from laboratory developed tests to companion diagnostics
  • Reviewing a case study demonstrating successful transition of CMC processes in line with new regulations
  • clock

    14:00

    Session Reserved for EdgeOne Medical

    clock

    14:30

    Advancing the Future of Obesity Therapies

    Kailera Therapeutics - Senior Representative

    Kailera Therapeutics - Senior Representative, , Kailera Therapeutics

  • Sharing updates on Kailera’s vision, therapeutic priorities and strategy for transforming obesity care
  • Providing a pipeline snapshot outlining core programs and current clinical milestones
  • Exploring the central role of GLP-1 and related pathways in driving improved outcomes for obesity and metabolic disorders
  • Demonstrating patient impact by showing how novel weight management treatments address unmet needs and support long-term health improvements
  • clock

    15:00

    Afternoon Networking Break

    clock

    15:30

    Session Reserved for Kindeva

    Kindeva - Senior Representative

    Kindeva - Senior Representative, , Kindeva

    clock

    16:00

    Panel Discussion: Evolving Strategies for High Volume Drug Delivery Platforms

  • De-risking the transition to large-volume self-administration by balancing viscosity, flow, injection forces, wear time and patient usability when moving from clinic to home
  • Examining patient journey realities that influence adoption including training burden, self-injection confidence, caregiver involvement and the role of digital support and connected features
  • Evaluating platform selection beyond the device itself by considering fill-finish compatibility, component and supply readiness and scalability across indications
  • Assessing where platforms are gaining ground by comparing adoption drivers for handheld versus on- or near-body devices in the US market and identifying what must change for the next wave
  • clock

    16:45

    Chair’s Closing Remarks and Close of Conference

    Kinsuk Shah, Sr. AD Combination Product Steward, Boehringer Ingelheim

    Confirmed Speakers Include:

    Product Development Research Engineer
    Bristol Myers Squibb
    Sr. Director and Head of Drug Product and Device Development
    Vir Biotechnology
    Assistant Director, Drug Delivery Device Development
    Ionis Pharmaceuticals, Inc
    Chief Executive Officer
    Ventura Solutions
    Associate Director
    Acadia Pharmaceuticals
    EdgeOne Medical
    Senior Director, Business Development
    West Pharmaceutical Service
    Haselmeier
    Head, Global Regulatory Affairs - (CoE): Emerging Technologies, Combination Products, and Devices
    AbbVie
    Co-CEO
    Credence MedSystems, Inc.
    Kailera Therapeutics
    Vice President - Global Head of Device Quality
    Genentech
    Sr. AD Combination Product Steward
    Boehringer Ingelheim
    Director, R&D Combination Product Development
    AbbVie
    Senior Principal Engineer
    Genentech
    Distinguished Engineer
    JnJ Innovative Medicine
    Mitsubishi Gas Chemical
    Director, Head of Human Factors Engineering
    Genentech
    Executive Director, Pharmaceutical Development
    Ionis Pharmaceuticals
    Protagonist Therapeutics
    Protagonist Therapeutics
    BioPhorum
    Head of Combination Products Operations
    Amgen
    Head of Combination Products Operations
    Amgen
    SHL Medical
    Vice President & Head, Pharmaceutical Development
    Ionis Pharmaceuticals
    Suttons Creek
    Senior Principal Research Scientist
    AbbVie

    Gold Sponsors

    Sponsors

    Exhibitors

    Official Media Partner

    VENUE

    San Diego Marriott La Jolla

    4240 La Jolla Village Drive, La Jolla , San Diego, California , USA

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing SMi Group Trading As SAE Media Group. SMi Group Trading As SAE Media Group books all hotel rooms directly. If you are approached by a third-party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third-party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Editor’s Corner

    Stay informed on the latest developments in Pre-Filled Syringes by subscribing to SAE Media Group's monthly newsletter
    SUBSCRIBE

    Sponsors and Exhibitors


    BD Medical - Pharmaceutical Systems

    Gold Sponsors
    http://drugdeliverysystems.bd.com

    As a partner of choice for the pharmaceutical and biotech companies across the globe, BD Medical - Pharmaceutical Systems provides a broad range of ready-to-use drug delivery systems including glass and plastic prefillable syringes, safety and shielding systems, self-injection systems and connected solutions that ensure smooth delivery, regardless of drug complexity, viscosity and dosing volume. We offer our expertise and resources to support their product launch and life cycle management through consultative, analytical and clinical services to help ensure drug compatibility and seamless systems integration, while accelerating time-to-market and reducing risk.

    More information available @ drugdeliverysystems.bd.com

    Contact us @ drugdeliverysystems.bd.com/contact-us



    SHL Medical

    Gold Sponsors
    http://www.shl-medical.com

    SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Driven by our purpose of “enabling patients’ independence”, we partner with leading pharma and biotech companies to develop self-injection systems and digital solutions that enhance patients’ treatment experience and quality of life. Our customers benefit from our proven track record and scalable, global manufacturing excellence, with locations in Switzerland, USA, Sweden, and Taiwan. By focusing on innovation, we challenge the status quo and shape the future of state-of-the-art drug delivery. We cover the entire drug delivery value chain, providing piece of mind through our end-to-end services, from design, development, to final assembly, labeling, and packaging.


    Steri-Tek

    Gold Sponsors
    http://www.steri-tek.com

    Steri-Tek, based in Fremont, CA, with a new facility in Lewisville, TX is a high-volume E-beam/X-Ray contract sterilizer and R&D innovation center serving the medical device, biotech, pharmaceutical and other industries. Steri-Tek is an ISO 11137 and ISO 13485 certified, FDA registered, DEA licensed as well as State of California Medical Device and Drug Manufacturing licensed facility.

    The California facility boasts two state-of-the-art 10 MeV, 20 KW linear accelerators. The Texas facility utilizes two state-of-the-art 10 MeV, 30 KW linear accelerators. Both offer simultaneous beam processing that allows for high volume production, providing uniform dose to the product without having to rotate the customer’s boxes. This DualBeam™ configuration significantly increases efficiencies, expands product options, and serves as an effective back-up for the accelerators. Steri-Tek has developed a proprietary system for radiation sensitive materials such as drugs/biologics, combination devices, bioabsorbables, implantables, advanced polymers and other complex products.

    Steri-Tek offers;

    • Turnkey Validation Services (per ISO 11137 VDmax and Method I)

    • Rapid Turnaround on Routine Sterilization Processing (48 hours standard with RUSH 24 hour and 4 hour turnaround available)

    • DualBeam™ E-beam/X-ray processing (Highest up time in industry)

    • Expert Consultation Services to optimize E-beam/X-ray sterilization processing and throughput of complex devices



    Suttons Creek

    Gold Sponsors
    http://www.suttonscreek.com

    Suttons Creek is pharma’s device team. Any company adopting combination product technology needs an experienced combination products team working alongside their drug team, including specialists in areas like quality, regulatory, vendor selection and management, systems engineering, risk management, clinical development, and commercialization. Suttons Creek has over 650 years of combined experience and 120+ combination product projects under its belt, with a talent pool of subject matter experts that specialize in all aspects of combination product development from strategic planning through device development to launch and postmarket activities. We can be any or all things combination product to a client, consulting hour by hour or engaging in strategic partnerships to achieve milestones, lift roadblocks, fill knowledge gaps, and drive program success.



    West Pharmaceutical Services

    Gold Sponsors
    https://www.westpharma.com/

    West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.

    Sponsors


    Credence MedSystems

    Sponsors
    http://www.credencemed.com

    Credence MedSystems is an innovator in injectable drug delivery devices. Credence’s philosophy of Innovation Without Change results in products that impress and protect end-users while preserving pharma’s existing processes, sourcing strategies and preferred primary package components. The Companion® family of syringe systems includes proprietary needle-retraction technology, reuse prevention and other critical safety and usability features in Staked and Luer needle formats. The Dual Chamber platform offers single-step mixing and injection for drugs requiring reconstitution at the time of delivery. Additional products such as metered dose devices, multi-length staked needles and other novel devices address the needs of specific therapeutic markets.


    Datwyler

    Sponsors
    https://healthcare.datwyler.com/

    Datwyler provides high-quality, system-critical elastomer components and has a leading position in the global healthcare market. Within the healthcare solutions business area, Datwyler develops, designs, and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment of tomorrow. Looking back onto more than 100 years of history, Datwyler is a reliable partner, now and in the future!


    EdgeOne Medical

    Sponsors
    http://www.edgeonemedical.com/

    EdgeOne Medical is a leading global Contract Device Development Organization, serving as the trusted testing and device development partner for more than half of the top 20 global pharmaceutical companies. As experts in compliant device development from benchtop to commercialization, we leverage our extensive industry knowledge, advanced in-house laboratory, and ISO 13485 certified Quality Management System to accelerate and derisk the development journey for our clients. EdgeOne Medical’s ability to get it “Right First Time” has made us the preferred partner for many key players in emerging pharma and big pharma. Our track record also includes supporting the combination product device development for several newly acquired emerging pharmaceutical companies representing the largest deals in the last year.


    Haselmeier

    Sponsors
    https://haselmeier.com/en/

    o Haselmeier, the drug delivery device business of medmix, designs, develops and manufactures advanced drug delivery systems such as pen injection systems and autoinjectors. Patient comfort and customers’ needs are always at the heart of the company’s practices. With its broad portfolio of technologies and services, Haselmeier delivers user-friendly injection systems that enable patients to self-administer their medication reliably and accurately. Haselmeier is known for its excellent and long-standing track record in providing these innovative drug delivery devices based on its proprietary IP business model. The company collaborates closely with its customers in the pharmaceutical and biopharmaceutical industries. Medmix, with its precision injection molding capabilities and expertise in liquid micro-dosing plus financial strength and global footprint, helps Haselmeier accelerate innovation in healthcare. With more than 100 years of expertise in the development and manufacture of drug delivery devices, our global footprint, nearly 250 distinguished and motivated experts, more than 200 patents granted, and numerous patents pending, Haselmeier remains committed to developing innovative solutions that support our customers and help improve the health of millions of people worldwide.



    Kindeva

    Sponsors
    https://www.kindevadd.com/about-us/

    As a purpose-fueled drug delivery CDMO, we leverage our specialist injectable, inhalation and dermal expertise to accelerate your product’s journey and make tomorrow’s possibilities a reality.

    From development to commercial manufacturing and beyond, amplify your product’s impact with our exceptional-by-design CDMO solutions.

    Our Bridgeton facility has over 155,000 sq. ft. of dedicated aseptic operations space, including state-of-the-art laboratories and formulation suites, alongside almost 11,000 sq. ft. of fill suites to ensure the highest levels of quality and patient safety.

    Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.



    Mitsubishi Gas Chemical

    Sponsors
    https://www.mgc.co.jp/eng/products/abd/oxycapt.html

    Mitsubishi Gas Chemical is a leading company in the field of oxygen barrier and absorbing technologies. Based on these technologies and experiences, we have successfully developed multilayer plastic vial and syringe having excellent oxygen, ultra violet and water vapor barrier. The products make it possible to replace glass with plastic for injectable drugs.


    Ventura Solutions

    Sponsors
    http://www.ventura-solutions.com

    Ventura Solutions is a reputable end-to-end medical device and combination product consulting, staffing, and training firm. With our deep industry expertise spanning medical devices and combination products, coupled with an outstanding talent pool, we stand out as the preferred option for a diverse array of projects. On the consulting side, we integrate seamlessly into your team and manage small to complex Statement of Work (SOW) projects. On the staffing side, we help source, screen, and on-board reputable employees to fill temporary, temp to permanent, and permanent job openings. We accelerate product development, keep products compliant, and help build great organizations.

    Exhibitors


    Altaviz

    Exhibitors
    https://www.altaviz.com/

    Bringing complex therapies to life. High-viscosity, large-volume, and complex-molecule therapies now define today’s pharmaceutical pipelines. Delivering them successfully requires drug delivery systems purpose-built for modern formulation demands, not legacy assumptions. Our solutions enable innovators to bring next-generation biologics, gene therapies, and long-acting injectables to patients with the capacity, consistency, and control required for reliable, patient-ready performance. While the industry continues to debate how best to address large-volume and high-viscosity delivery, our systems are already proven in real-world use. Millions of therapies have been delivered globally through commercialized, validated platforms engineered to handle viscosities exceeding 100 cP, volumes beyond 2.25 mL, molecular weights over 1,000 kDa, and concentrations above 150 mg/mL, all through patient-friendly needle sizes under 27G. Sister companies Altaviz and Picocyl design and manufacture these advanced solutions in U.S.-based ISO Class 8 cleanrooms, delivering medical-grade quality, performance, reliability, compliance, and manufacturability for the most demanding therapies worldwide.


    Amcor

    Exhibitors
    https://www.amcor.com/products/healthcare

    Amcor is a global leader in packaging solutions for consumer and healthcare products. With industry-leading innovation capabilities, global scale and technical expertise, we help our customers grow and meet the needs of millions of consumers every day. Our teams develop responsible, more sustainable packaging in flexible and rigid formats across multiple materials. Supported by a commitment to safety, ~70,000 colleagues across ~140 countries bring our global capabilities to local customers and provide local access to global brands. Our work is guided by our purpose of elevating customers, shaping lives and protecting the future.


    Ensera

    Exhibitors
    https://www.ensera.com/

    Ensera is a global contract design and manufacturing organization (CDMO) specializing in complex product design, manufacturing and supply chain solutions for pharmaceuticals, drug-device combination products and medical devices. With facilities in the United States, Europe and Southeast Asia, we support leading pharma and MedTech innovators on their route to market, with services including design, manufacturing, final assembly, secondary packing, supply chain management and regulatory support.


    Gerresheimer

    Exhibitors
    http://www.gerresheimer.com

    Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The company offers a comprehensive portfolio of pharmaceutical primary packaging, drug delivery systems and digital solutions. Gerresheimer ensures that medicines reach patients safely and can be administered reliably. With around 12,000 employees and 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for the regional markets with a focus on the pharma industry.



    MGS

    Exhibitors
    http://mgsmfg.com

    A global provider of healthcare contract development and manufacturing solutions, MGS provides the right balance to drive vital innovations: robust, vertically integrated global capabilities combined with the strong customer focus and seamless collaboration of an agile partner. That’s why we’re the healthcare CDMO of choice for today’s leading Pharma, Diagnostic and MedTech companies.



    Nipro PharmaPackaging

    Exhibitors
    http://www.nipro-group.com

    Nipro PharmaPackaging is specialized in developing and manufacturing advanced pharma packaging products and complete packaging solutions for early development drugs or the enhancement of packaging solutions for existing drugs. With a worldwide manufacturing footprint of 19 plants, multiple sales offices, and lab services, Nipro offers an exceptional service platform. Through our personnel, products, and services, Nipro PharmaPackaging enables you to provide a safer and healthier administration to your customers. Nipro PharmaPackaging is part of Nipro Corporation Japan, established in 1954. As a leading global healthcare company with over 35,000 employees worldwide, Nipro serves the Pharmaceutical, Medical Device, and Pharmaceutical Packaging industries.


    Noxilizer

    Exhibitors
    https://noxilizer.com/

    Noxilizer is the expert in the application of the NO2 process within the supply chain. Noxilizer sells sterilization equipment to pharmaceutical, biotech, and medical device manufacturers and also offers contract sterilization services.



    Owen Mumford

    Exhibitors
    http://www.owenmumford.com

    Owen Mumford Pharmaceutical Services is a specialist in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech & generics industries. These include single dose and multidose reusable and disposable auto-injectors, pens and syringes for subcutaneous and intramuscular administration. Our innovative products are designed to meet both the need of our pharmaceutical partners and their patients by facilitating ease of use and improving safety and patient compliance. Our devices are also designed with aim of reducing complexity and risk for the pharmaceutical & biotech industry in the development of their combination products.

    For more information please visit https://www.ompharmaservices.com/



    PCI Pharma Services

    Exhibitors
    http://www.pciservices.com

    PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialization, delivering speed-to-market and commercial success for our customers. Our core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply. We partner with clients in providing innovative technologies, flexible solutions, and an integrated supply network supporting lifesaving medicines destined to over 100 countries around the world. We support clients with a dedication to providing the industry’s leading experience, exemplified in our operational flexibility, delivery, and commitment to safety, supported by industry leading technologies and an exemplary quality and regulatory record. This has allowed us to be the partner of choice for leading pharmaceutical companies around the world, operating as a seamless extension of their business.


    PromiseMed Medical Devices Inc.

    Exhibitors
    http://

    PromiseMed is the manufacturer and supplier of device components and consumables for injectable drug delivery and combination products. Our offerings include a cartridge-based disposable pen injector platform delivered as key components—housing, cartridge holder, and cap—enabling pharmaceutical partners to integrate their drug-filled cartridges into a pen format. In addition, we provide drug-free (unfilled) components for pre-filled syringe systems, supporting customer filling and final assembly. To complete injection workflows in home and clinical settings, we also supply pen needles ( including safety pen needles to reduce accidental needlestick injury)  with multiple length options, alcohol swabs, and sharps containers. Promise for Quality. Promise for Health. Promise for Life. PromiseMed - Professional Manufacturer for Premium Healthcare Products.


    Stevanato

    Exhibitors
    https://www.stevanatogroup.com/en/

    Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value-added solutions to clients. To learn more, visit: www.stevanatogroup.com


    Terumo

    Exhibitors
    https://www.terumopharmaceuticalsolutions.com/en-EMEA

    As Part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety.

    Globally trusted for quality and precision, we offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services.

    We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral drug delivery.

    Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies, including CDMO services for all parenteral applications.

    We listen. We question. We deliver.



    Ypsomed

    Exhibitors
    http://yds.ypsomed.com/en/

    Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid injectable medications. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.


    Media Partners


    ONdrugDelivery

    Official Media Partner
    http://ondrugdelivery.com

    ONdrugDelivery provides readers throughout global pharma/biopharma with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: ondrugdelivery.com/subscribe

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    San Diego Marriott La Jolla

    4240 La Jolla Village Drive
    La Jolla
    San Diego 92037
    USA

    San Diego Marriott La Jolla

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.

    Join the Loitering Munitions community

    Keep up to date with industry news, insights, and community updates FREE and direct to your inbox every month!
    * - required fields
    You can unsubscribe at any time. For full details see our Privacy Policy

    Download the 2026 Defence Events Calendar here to view the full list of SAE Media Group’s conferences this year

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.